Table 1.

Effect of AG14361 on topotecan-mediated growth inhibition in PARP-1+/+ and PARP-1−/− cells

GI50 (nmol/L)
PF50
TopotecanTopotecan + 0.4 μmol/L AG14361
PARP-1+/+65.0 ± 7.019.5 ± 4.3*3.4 ± 0.4
PARP-1−/−20.8 ± 2.0*15.6 ± 0.61.4 ± 0.1
Sensitivity ratio3 ± 0.21.3 ± 0.5
  • NOTE: Growth of cells treated with topotecan in the presence or absence of AG14361 for 5 days continuously determined by sulforhodamine B assay and expressed as a percentage of the relevant DMSO or 0.4 μmol/L AG14361-treated control. Mean ± SE GI50 of three independent experiments. PF50 is the potentiation factor, the ratio of GI50 topotecan alone to GI50 topotecan plus AG14361 calculated from GI50 of individual experiments.

  • * P < 0.001, Student's paired t test compared with PARP-1+/+ treated with camptothecin alone.

  • Not significantly different from PARP-1+/+ treated with topotecan plus AG14361.

  • P < 0.05, Student's paired t test compared with PARP-1-/- treated with camptothecin alone.